Get the Stockscreener App
2.39
8.14%
0.18
After Hours:
2.29
-0.10
-4.18%
Zentalis Pharmaceuticals Inc stock is traded at $2.39, with a volume of 841.90K.
It is up +8.14% in the last 24 hours and up +34.27% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$2.21
Open:
$2.24
24h Volume:
841.90K
Relative Volume:
0.67
Market Cap:
$154.75M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.5264
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-1.65%
1M Performance:
+34.27%
6M Performance:
+73.19%
1Y Performance:
+10.65%
1-Day Range:
$2.17
$2.39
1-Week Range:
$2.17
$2.85
52-Week Range:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.39 | 143.10M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals PAO sells $7.8k in stock By Investing.com - Investing.com India
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Will Zentalis Pharmaceuticals Inc be affected by tariffsQuarterly Trade Review & Daily Technical Forecast Reports - baoquankhu1.vn
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - GlobeNewswire
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Stock Report: Is Zentalis Pharmaceuticals Inc currently under institutional pressureDay Trade & Smart Swing Trading Alerts - baoquankhu1.vn
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Dow Update: How Zentalis Pharmaceuticals Inc stock reacts to job market data2025 Technical Patterns & Verified Swing Trading Watchlist - Bộ Nội Vụ
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Yahoo Finance
Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens - timothysykes.com
Zentalis outlines 2026 milestones for azenosertib program - The Globe and Mail
Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments - StocksToTrade
Trade Recap: Will Zentalis Pharmaceuticals Inc stock outperform tech sector in 20252025 Performance Recap & Long-Term Safe Investment Plans - Bộ Nội Vụ
Zentalis Pharmaceuticals Surges with Azenosertib Developments - timothysykes.com
Zentalis Pharmaceuticals, Inc. Provides Corporate Update on Azenosertib Development - TradingView — Track All Markets
Azenosertib plans at Zentalis (NASDAQ: ZNTL) with cash runway to 2027 - Stock Titan
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update - Quiver Quantitative
Aug Weekly: Is Zentalis Pharmaceuticals Inc. stock ready for breakoutPortfolio Update Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Major Investor Makes Bold Move on Zentalis Pharmaceuticals Stock - TipRanks
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Insider Buying: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Purchases 6,459,973 Shares of Stock - MarketBeat
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Nigeria
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonWeekly Stock Report & Real-Time Volume Triggers - Улправда
Price Action: Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Quarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Will Zentalis Pharmaceuticals Inc. stock outperform tech sector in 2025Trade Risk Assessment & Risk Adjusted Buy and Sell Alerts - Улправда
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - Улправда
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):